Case Report

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient

Table 1

Evolution of the viral resistances according to time.

Sample dates28 December 200531 January 200711 January 200813 September 200814 January 200926 July 201020 October 201109 September 201619 May 201705 March 2021Cumulative

Viral load (copies/mL)67000>100000>10000031000633003430056357200039800020200
CD4 count (/μL)4881091412031733833361113591

NRTI
Lamivudine (3TC)ILLSILLRILLSRRR
Abacavir (ABC)RIRRRRILLIRIRR
Zidovudine (AZT)RRRRRIRIRRR
Stavudine (D4T)RRRRRIRIRRR
Didanosine (DDI)RRRRRIRRRR
Emtricitabine (FTC)ILLSILLRILLSRRR
Tenofovir (TDF)RIRRIRRILLSSPR

NNRTI
Doravirine (DOR)SSSSSPIRIRILLIR
Efavirenz (EFV)SSSSIRRRRR
Etravirine (ETR)SSSSIRIRIRIRIR
Nevirapine (NVP)SSSSRRRRR
Rilpivirine (RPV)SSSSIRRRIRR

PI
Atazanavir (ATV/r)RSRRRRRRR
Darunavir (DRV/r)ILLSILLILLILLRRRR
Fosamprenavir (FPV/r)RSRRRRRRR
Indinavir (IDV/r)RSRRRRRRR
Lopinavir (LPV/r)RSRRRRRRR
Nelfinavir (NFV)RSRRRRRRR
Ritonavir (/r)RSRRRRRRR
Saquinavir (SQV/r)RSRRRRRRR
Tipranavir (TPV/r)RSRRRRRRR

INSTI
Bictegravir (BIC)SSSPSPSPSP
Cabotegravir (CAB)SSILLILLILLILL
Dolutegravir (DTG)SSSPSPSPSP
Elvitegravir (EVG)SSIRIRIRIR
Raltegravir (RAL)SSRRRR

Attachment inhibitors
Maraviroc (MVC)CXCR4 use (phenotypic)CCR5 use (FPR 17%)CXCR4 use (FPR 0.1%)

INSTI: integrase strand transfer inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, PI: protease inhibitor; ILL: low-level resistance, IR: intermediate resistance, R: high-level resistance, S: susceptible, SP: potential low-level resistance, —: result not available. HD: hemodialysis, PD: peritoneal dialysis, eGFR: estimated glomerular filtration rate, IU: international unit, PA: alkaline phosphatase, Hb: hemoglobin, cp/ml: copies/milliliter, SC: subcutaneous.